Vivos Therapeutics Inc (VVOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has a cash flow conversion efficiency ratio of -1.643x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.16 Million) by net assets ($2.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vivos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Vivos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Vivos Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Vivos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ta Win Holdings Bhd
KLSE:7097
|
-0.034x |
|
Venzee Technologies Inc
V:VENZ
|
-0.012x |
|
Pioneer Embroideries Limited
NSE:PIONEEREMB
|
0.057x |
|
Bekasi Asri Pemula Tbk
JK:BAPA
|
-0.003x |
|
ECOUP OYJ EO 1
F:62H
|
N/A |
|
ACE LIBERTY+STONE LS -25
F:8MW
|
N/A |
|
Kinovo PLC
LSE:KINO
|
-0.845x |
|
Uma Exports Limited
NSE:UMAEXPORTS
|
0.041x |
Annual Cash Flow Conversion Efficiency for Vivos Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Vivos Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Vivos Therapeutics Inc (VVOS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.95 Million | $-12.69 Million | -1.596x | +94.51% |
| 2023-12-31 | $411.00K | $-11.95 Million | -29.066x | -612.43% |
| 2022-12-31 | $4.80 Million | $-19.59 Million | -4.080x | -562.18% |
| 2021-12-31 | $25.54 Million | $-15.73 Million | -0.616x | -83.50% |
| 2020-12-31 | $16.92 Million | $-5.68 Million | -0.336x | -118.50% |
| 2019-12-31 | $-2.94 Million | $-5.34 Million | 1.815x | +264.83% |
| 2018-12-31 | $4.83 Million | $-5.31 Million | -1.101x | -- |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring… Read more